Abstract
Voiding of the bladder is the result of a parasympathetic muscarinic receptor activation of the detrusor smooth muscle. However, the maintenance of continence and a normal bladder micturition cycle involves a complex interaction of cholinergic, adrenergic, nitrergic and peptidergic systems that is currently little understood. The cholinergic component of bladder control involves two systems, acetylcholine (ACh) released from parasympathetic nerves and ACh from non-neuronal cells within the urothelium. The actions of ACh on the bladder depend on the presence of muscarinic receptors that are located on the detrusor smooth muscle, where they cause direct (M3) and indirect (M2) contraction; pre-junctional nerve terminals where they increase (M1) or decrease (M4) the release of ACh and noradrenaline (NA); sensory nerves where they influence afferent nerve activity; umbrella cells in the urothelium where they stimulate the release of ATP and NO; suburothelial interstitial cells with unknown function; and finally, other unidentified sites in the urothelium from where prostaglandins and inhibitory/relaxatory factors are released. Thus, the actions of muscarinic receptor agonists and antagonists on the bladder may be very complex even when considering only local muscarinic actions. Clinically, muscarinic antagonists remain the mainstay of treatment for the overactive bladder (OAB), while muscarinic agonists have been used to treat hypoactive bladder. The antagonists are effective in treating OAB, but their precise mechanisms and sites of action (detrusor, urothelium, and nerves) have yet to be established. Potentially more selective agents may be developed when the cholinergic systems within the bladder are more fully understood.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006
Abrams P, Shah PJR, Feneley RCL (1981) Voiding disorders in the young male adult. Urology 18:107–113
Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49
Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C et al (2010) Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 29:213–240
Anagnostara SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognition dysfunction in acetylcholine m1 muscarinic receptor mutant mice. Nat Neurosci 6:51–58
Andersson KE (2002) Bladder activation: afferent mechanisms. Urology 59(5 Suppl 1):43–50
Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 43:1–5
Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, Haab F, Vela Navarrete R (1999) The pharmacological treatment of urinary incontinence. BJU Int 84(9):923–947
Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169(6):2253–2256
Awad S (1985) Clinical use of bethanechol. J Urol 134:523–524
Banks FCL, Knight GE, Calvert RC, Morgan RJ, Burnstock G (2005) Alterations in purinergic and cholinergic components of contractile responses of isolated detrusor contraction in a rat model of partial bladder outlet obstruction. BJU Int 97:372–378
Barlow RB, Weston-Smith P (1985) The relative potencies of some agonists at M2 muscarinic receptors in guinea pig ileum, atria and bronchi. Br J Pharmacol 85:437–440
Baselli EC, Brandes SB, Luthin GR, Ruggieri MR (1999) The effect of pregnancy and contractile activity on bladder muscarinic receptor subtypes. Neurourol Urodyn 18(5):511–520
Bayliss M, Wu C, Newgreen AR, Mundy CH, Fry CH (1999) A quantitative study of atropine-resistant contractile responses in human bladder detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 162:1833–1839
Birder LA (2010) Urothelial signaling. Auton Neurosci 153(1–2):33–40
Birder LA, Apodaca G, de Groat WC, Kanai AJ (1998) Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 275(2 Pt 2):F226–F229
Blake-James BT, Rashidian A, Ikeda Y, Emberton M (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99(1):85–96
Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M (2009) Double anticholinergic therapy for refractory overactive bladder. J Urol 182(4 Suppl):2033–2038
Boy S, Schurch B, Mehnert U, Mehring G, Karsenty G, Reitz A (2007) The effects of tolterodine on bladder-filling sensations and perception thresholds to intravesical electrical stimulation: method and initial results. BJU Int 100(3):574–578
Braverman AS, Kohn IJ, Luthin GR, Ruggieri MR (1998a) Prejunctional M1 facilitory and M2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol 274:R517–R523
Braverman AS, Luthin GR, Ruggieri MR (1998b) M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol Regul Integr Comp Physiol 275:R1654–R1660
Braverman AS, Doumanian LR, Ruggieri MR (2006b) M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. J Pharmacol Exp Ther 316:875–880
Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Kummer W, Lips KS (2007) Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 80:2303–2307
Burnstock G (2001) Purinergic signalling in the lower urinary tract. In: Abbracchio MP, Williams M (eds) Handbook of experimental pharmacology. Springer, Berlin, pp 423–515
Burnstock G (2009) Purinergic cotransmission. Exp Physiol 94(1):20–24
Canda AE, Chapple CR, Chess-Williams R (2009) Pharmacologic responses of the mouse urinary bladder. Cent Eur J Med 4(2):192–197
Chancellor MB, Kaplan SA, Blavias JG (1992) The cholinergic and purinergic components of detrusor contractility in a whole rabbit bladder model. J Urol 148:906–909
Chapple CR, Radley SC, Martin SW, Sellers DJ, Chess-Williams R (2004) Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle. BJU Int 93(4):599–604
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562
Chess-Williams R (2002) Muscarinic receptors of the bladder: detrusor, urothelial and prejunctional. Auton Autocoid Pharmacol 22(3):133–145
Chess-Williams R, Chapple CR, Yamanishi T, Sellers DJ (2001) The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21(5–6):243–248
Choppin A (2002) Muscarinic receptors in isolated urinary bladder smooth muscle from different mouse strains. Br J Pharmacol 137(4):522–528
Choppin A, Eglen RM (2001a) Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle. Br J Pharmacol 133(7):1035–1040
Choppin A, Eglen RM (2001b) Pharmacological characterization of muscarinic receptors in dog ciliary and urinary bladder smooth muscle. Br J Pharmacol 132:835–842
Choppin A, Eglen RM, Hedge SS (1998) Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br J Pharmacol 124:883–888
D’Agostino G, Bolognesi ML, Lucchelli A, Vicini D, Balestra B, Spelta V, Melchiorre C, Tonini M (2000) Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. Br J Pharmacol 129:493–500
Daly DM, Chess-Williams R, Chapple C, Grundy D (2010) The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol 58(1):22–28
de Groat C (1997) A neurologic basis for the overactive bladder. Urology 50 (6A Suppl):36–52; discussion 53–56
de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147:S25–S40
de Groat WC, Yoshimura N (2010) Changes in afferent activity after spinal cord injury. Neurourol Urodyn 29(1):63–76
De Laet K, De Wachter S, Wyndaele JJ (2006) Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 25:156–161
De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169(5):1892–1895
Diokno AC, Brock BM, Brown MB et al (1986) Prevalence of urinary incontinence and other urological symptoms in the non-institutionalized elderly. J Urol 136:1022–1025
Ehlert FJ, Griffin MT, Abe DM, Vo TH, Taketo MM, Manabe T, Matsui M (2005) The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 313(1):368–378
Elbadawi A, Yalla SV, Resnick NM (1993) Structural basis of geriatric voiding dysfunction. II Aging detrusor: normal versus impaired contractility. J Urol 150:1657–1667
Fabiyi AC, Brading AF (2006) The use of the isolated mouse whole bladder for investigating bladder overactivity. J Pharmacol Exp Ther 319(3):1386–1394
Ferguson DR, Kennedy I, Burton TJ (1997) ATP is released from rabbit urinary bladder epithelium cells by hydrostatic pressure changes: a possible sensory mechanism? J Physiol 505:503–511
Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC (2002) M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136:641–643
Finkbeiner AE (1985) Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 134:443–449
Finney SM, Stewart LH, Gillespie JI (2007) Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system. BJU Int 100(3):668–678
Foote J, Glavind K, Kralidis G, Wyndaele JJ (2005) Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 48(3):471–477
Fovaeus M, Fujiwara M, Högestätt ED, Persson K, Andersson KE (1999) A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. J Urol 161(2):649–653
Fry CH, Skennerton D, Wood D, Wu C (2002) The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology 59:3–12
Gillespie JI, Harvey IJ, Drake MJ (2003) Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp Physiol 88(3):343–357
Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M (2009) Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 63(8):1198–1204
Grol S, Essers PBM, van Koeveringe GA, Martinez-Martinez P, de Vente J, Gillespie JI (2009a) M3 muscarinic receptor expression on suburothelial interstitial cells. BJU Int 104:398–405
Gunasena KT, Nimmo AJ, Morrison JF, Whitaker EM (1995) Effects of denervation on muscarinic receptors in the rat bladder. Br J Urol 76(3):291–296
Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, Birder LA (2007) Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 80(24–25):2298–2302
Harrison SC, Hunnam GR, Farman P, Ferguson DR, Doyle PT (1987) Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60(6):519–522
Hawthorn MH, Chapple CR, Cock M, Chess-Williams R (2000) Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 129:416–419
Hedlund P, Streng T, Lee T, Andersson K-E (2007) Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol 178:326–331
Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM (1997) Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120:1409–1418
Hegde SS, Eglen R (1999) Muscarinic receptor subtypes modulating smooth muscle contractility on the urinary bladder. Life Sci 64(6–7):419–428
Hegde SS, Mammen M, Jasper JR (2004) Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs 5(1):40–49
Hill S, Khullar V, Wyndaele JJ et al (2006) Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17:239–247
Igawa Y, Zhang X, Nishizawa O, Umeda M, Iwata A, Taketo MM, Manabe T, Matsui M, Andersson KE (2004) Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol 172(Part 1 of 2):2460–2464
Iijima K, De Wachter S, Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842–849
Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K (2002) M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 366(2):97–103
Inadome A, Yoshida M, Takahashi W, Yono M, Seshita H, Miyamoto Y, Kawano T, Ueda S (1998) Prejunctional muscarinic receptors modulating acetylcholine release in rabbit detrusor smooth muscles. Urol Int 61:135–141
Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315
Johnston L, Carson C, Lyons AD, Davidson RA, McCloskey KD (2008) Cholinergic-induced Ca2+ signaling in interstitial cells of Cajal from the guinea pig bladder. Am J Physiol Renal Physiol 294(3):F645–F655
Jositsch G, Papdakis T, Haberberger RV, Wolff M, Wess J, Kummer W (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379:389–395
Kaplan SA, Roehrborn CG, Dmochowski R et al (2006) Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68(2):328–332
Kay GG, Ebinger U (2008) Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62(11):1792–1800
Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z (2008) Fesoterodine DOSE response in subjects with overactive bladder syndrome. Urology 71(5):839–843
Kim JC, Yoo JS, Park EY, Hong SH, Seo SI, Hwang TK (2008) Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int 101:371–375
Kinder RB, Mundy AR (1985) Atropine blockade of nerve-mediated stimulation of the human detrusor. Br J Urol 57:418–421
Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007a) Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland. Arzneimittelforschung 57(2):92–100
Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, Matsuzawa S (2007b) Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 57(3):147–154
Krichevsky VP, Pagala MK, Vaydovsky I, Damer V, Wise GJ (1999) Function of M3 muscarinic receptor in the rat urinary bladder following partial outlet obstruction. J Urol 161:1644–1650
Krishnamoorthy S, Kekre NS (2009) Detrusor underactivity: to tone or not to tone the bladder? Indian J Urol 25(3):407–408
Kullmann FA, Artim DE, Beckel JM, Barrick S, de Groat WC, Birder LA (2008) Heterogeneity of muscarinic receptor mediated Ca2+ responses in cultured urothelial cells from rat. Am J Physiol Renal Physiol 294:F971–F981
Lamers WH (2009) BJUI Letters. BJU Int 104:1538–1539
Lazareno S, Birdsall NJ (1993) Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. Br J Pharmacol 109(4):1120–1127
Lazareno S, Buckley NJ, Roberts FF (1990) Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol Pharmacol 38(6):805–815
Lee S, Malhotra B, Creanga D, Carlsson M, Glue P (2009) A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 9:55
Longhurst PA, Leggett RE, Briscoe AK (1995) Characterization of the functional muscarinic receptors in the rat urinary bladder. Br J Pharmacol 116:2279–2285
Madeiro AP, Rufino AC, Sartori MGF, Baracat EC, Lima GR, Girao MJ (2006) The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomised, double-blind, placebo controlled study. Int Urogynecol J Pelvic Floor Dysfunct 17:248–252
Mansfield KJ, Lui L, Michelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089–1099
Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E (2009) Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther 328(3):893–899
Masters JG, Neal DE, Gillespie JI (1999) The contribution of intracellular Ca2+ release to contraction in human bladder smooth muscle. Br J Pharmacol 127:996–1002
Masunaga K, Yoshida M, Inadome A, Murakami S, Sugiyama Y, Satoji Y, Maeda Y, Ueda S (2008) Pharmacogical effects of solifenacin on human isolated urinary bladder. Pharmacology 82(1):43–52
Masunaga K, Yoshida M, Inadome A, Iwashita H, Miyamae K, Ueda S (2006) Prostaglandin E2 release from isolated bladder strips in rats with spinal cord injury. Int J Urol 13(3):271–276
Matsui M, Motomura D, Fujikawa T, Jiang J, Takahashi S, Manabe T, Taketo MM (2002a) Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci 22:10627–10632
Matsui M, Yamada S, Oki T, Manabe S, Taketo MM, Ehlert FJ (2004) Functional analysis of muscarinic acetylcholine receptors using knockout mice. Life Sci 75:2971–2981
Matsumoto Y, Miyazato M, Furata A, Torimoto K, Hirao Y, Chancellor MB, Yoshimura N (2010) Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats. Urology 75(4):862–867
McCloskey KD (2010) Interstitial cells in the urinary bladder–localization and function. Neurourol Urodyn 29(1):82–87
Michel MC, Hegde SS (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374(2):79–85
Michel MC, Weiland T, Tsujimoto G (2009) How reliable are G-protein coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 379:385–388
Miller K, DuBeau C, Bergmann M et al (2002) How does drug treatment improve urge incontinence? Neurourol Urodyn 32:186–199
Mills IW, Greenland JE, McMurray G et al (2000) Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol 163:646–651
Miyamoto Y, Yoshida M, Takahashi W, Inadome A, Yono M, Seshita H, Murakami S, Ueda S (2001) The effect of nitric oxide on acetylcholine release in the rabbit bladder. Eur J Pharmacol 428:59–67
Mori S, Kojima M, Sakai Y, Nakajima K (1999) Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nippon Ronen Igakkai Zasshi 36(7):489–494
Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P (2006) Localisation of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176(1):367–373
Ney P, Kumar Pandita R, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE (2008) Pharmacological characterisation of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 101:1036–1042
Nilvebrant L, Andersson KE, Gillberg PG et al (1997) Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 327:195
Noronha-Blob L, Lowe V, Patton A, Canning B, Costello D, Kinnier WJ (1989) Muscarinic receptors: relationships among phosphoinositide breakdown, adenylate cyclase inhibition, in vitro detrusor muscle contractions and in vivo cystometrogram studies in guinea pig bladder. J Pharmacol Exp Ther 249:843–851
Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W (2008) A systematic review and meta-analysis of randomised controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740–764
Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, Hatanaka T, Suzuki M, Sato S, Sasamata M, Miyata K (2007) Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 30(1):54–58
Persson K, Igawa Y, Mattiasson A, Andersson KE (1992) Effects of inhibition of the l-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107(1):178–184
Peters SLM, Schmidt M, Michel MC (2006) Rho kinase. A target for treating urinary bladder dysfunction? Trends Pharmacol Sci 27:492–497
Pontari MA, Braverman AS, Ruggieri MR et al (2004) The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 286:R874–R880
Pradidarcheep W, Labruyere WT, Dabhoiwala NF, Lamers WH (2008) Lack of specificity of commercially available antisera: better specifications needed. J Histochem Cytochem 56:1099–1111
Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379:397–402
Reilly K, Milsom I, Irwin D et al (2006) Prevalence of incontinence and overactive bladder: European results from the EPIC study. Eur Urol 5(Suppl):116
Reitstetter R, He DS, Gruener R (1994) Oxotremorine-M activates single nicotinic acetylcholine receptor channels in cultured Xenopus myocytes. Eur J Pharmacol 264(1):27–32
Reynard JM (2004) Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 14(1):13–16
Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C (2009) Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 28:52–57
Ruggieri MR, Braverman AS (2006) Regulation of bladder muscarinic receptor subtype by experimental pathologies. Auton Autocoid Pharmacol 26:311–325
Saito M, Kondo A, Kato T, Hasegawa S, Miyake K (1993) Response of the human neurogenic bladder to KCl, carbachol, ATP and CaCl2. Br J Urol 72(3):298–302
Sakakibara R, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2005) Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer’s disease. Neurourol Urodyn 24(3):273–275
Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, Dahl NV (2007) Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multi-centre, community-based, randomized study. BJU Int 99(4):836–844
Schneider T, Fetscher C, Krege S, Michel MC (2004) Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 309:1148–1153
Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J, Basile AS, Alzheimer C, Wess J (2004) M2 muscarinic acetylchline receptor knock-out mice show deficits in behavioural flexibility, working memory and hippocampal plasticity. J Neurosci 24:10117–10127
Sellers DJ, Yamanishi T, Yasuda K, Couldwell C, Chapple CR, Chess-Williams R (2000) M3 muscarinic receptors but not M2 mediated contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol 20(3):171–176
Sibley GNA (1984) A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J Physiol 354:431–443
Sink KM, Thomas J III, Xu H, Craig B, Kritchevsky S, Sands LP (2008) Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 56(5):847–853
Sjogren C, Andersson KE, Husted S, Mattiasson A, Moller-Madsen B (1982) Atropine resistance of transmurally stimulated isolated human bladder muscle. J Urol 128:1368–1371
Somogyi GT, de Groat WC (1999) Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci 64(6–7):411–418
Somogyi GT, Tanowitz M, De Groat WC (1994) M1 muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder. J Physiol 480(Pt 1):81–89
Somogyi GT, Zernova GV, Yoshiyama M, Yamamoto T, de Groat WC (1998) Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol 125(2):241–246
Somogyi GT, Yokoyama EA, Szell EA, Smith CP, de Groat WC, Huard J, Chancellor MB (2002) Effect of cryoinjury on the contractile parameters of bladder strips: a model of impaired detrusor contractility. Brain Res Bull 59:23–28
Staskin DR (2005) Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 22(12):1013–1028
Staskin DR, Robinson D (2009) Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 10(18):3103–3111
Stengel PW, Gomeza J, Wess J, Cohen ML (2000) M2 and M4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 292:877–885
Stevens LA, Sellers DJ, McKay NG, Chapple CR, Chess-Williams R (2006) Muscarinic receptor function, density and G-protein coupling in the overactive diabetic rat bladder. Auton Autocoid Pharmacol 26(3):303–309
Stevens LA, Cr C, Chess-Williams R (2007) Human idiopathic and neurogenic overactive bladders and the role of M(2) muscarinic receptors in contraction. Eur Urol 52(2):531–538
Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336
Sui GP, Wu C, Fry C (2004) Electrical characteristics of suburothelial cells isolated from the human bladder. J Urol 171:938–943
Takeuchi T, Yamashiro N, Kawasaki T, Nakajima H, Azuma YT, Matusui M (2008) The role of muscarinic receptor subtypes in acetylcholine release from the urinary bladder obtained from muscarinic receptor knockout mouse. Neuroscience 156:381–389
Taylor JA, Kuchel GA (2006) Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54:1920–1932
Tobin G, Sjogren C (1998) Prejunctional facilitatory and inhibitory modulation of parasympathetic nerve transmission in the rabbit urinary bladder. J Auton Nerv Syst 68:153–156
Tong YC, Cheng JT, Hsu CT (2006) Alterations of M2 muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder. Neurosci Lett 406:216–221
Trendelenburg AU, Gomeza J, Klebroff W, Zhou H, Wess J (2003) Heterogeneity of presynaptic muscarinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice. Br J Pharmacol 138(3):469–480
Trendelenburg AU, Meyer A, Wess J, Starke K (2005) Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice. Br J Pharmacol 145(8):1153–1159
Tubaro A (2004) Defining overactive bladder: epidemiology and burden of disease. Urology 64(6 Suppl 1):2–6
Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, de Miguel F (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176:1673–1678
Wagg A, Wyndaele JJ, Sieber P (2006) Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 4(1):14–24
Wang P, Luthin GR, Ruggieri MR (1995) Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273:959–966
Wein AJ, Malloy TR, Shofer F, Raezer DM (1980) The effects of bethanechol chloride on urodynamic parameters in normal women and in women with significant residual urine volumes. J Urol 124:397–399
Wessler I, Roth E, Deutsch C, Brockerhoff P, Bittinger F, Kirkpatrick CJ, Kilbinger H (2001) Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transports. Br J Pharmacol 134:951–956
Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD (2003) Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 138:757–766
Womack KB, Heilman KM (2003) Tolterodine and memory: dry but forgetful. Arch Neurol 60(5):771–773
Wu C, Bayliss M, Newgreen D, Mundy AR, Fry CH (1999) A comparison of the mode of action of ATP and carbachol on isolated human detrusor smooth muscle. J Urol 162:1840–1847
Wuest M, Weiss A, Waelbroeck M, Braeter M, Kelly LU, Hakenberg OW, Ravens U (2006) Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 374(2):87–97
Yamada M, Miyakawa T, Duttaroy A, Yamanaka A, Moriguchi T, Makita R, McKinzie DL, Felder CC, Deng CX, Faraci FM, Wess J (2001) Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410:207–212
Yamaguchi O, Shishido K, Tamura K, Ogawa T, Fujimura T, Ohtsuka M (1996) Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156:1208–1213
Yamanishi T, Yasuda K, Chapple CR, Chess-Williams R (2000) The role of M2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol 131(7):1482–1488
Yamazaki T, Muraki Y, Anraku T (2011) In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 384:319–329
Yokota T, Yamaguchi O (1996) Changes in cholinergic and purinergic neurotransmission in pathologic bladder of chronic spinal rabbit. J Urol 156(5):1862–1866
Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H (2005) Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 174(5):2032–2036
Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A (2004) Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63:17–23
Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, Murakami S (2006) Non-neuronal cholinergic system in human bladder urothelium. Urology 67:425–430
Zagorodnyuk VP, Gregory S, Costa M, Brookes SJ, Tramontana M, Giuliani S, Maggi CA (2009) Spontaneous release of acetylcholine from autonomic nerves in the bladder. Br J Pharmacol 157(4):607–619
Zarghooni S, Wunsch J, Bodenbenner M, Bruggmann D, Grando SA, Schwantes U, Wess J, Kummer W, Lips KS (2007) Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. Life Sci 80:2308–2313
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sellers, D.J., Chess-Williams, R. (2012). Muscarinic Agonists and Antagonists: Effects on the Urinary Bladder. In: Fryer, A., Christopoulos, A., Nathanson, N. (eds) Muscarinic Receptors. Handbook of Experimental Pharmacology, vol 208. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-23274-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-23274-9_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-23273-2
Online ISBN: 978-3-642-23274-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)